Pharmacies; compounding of certain active pharmaceutical ingredients; provisions
Impact
If enacted, HB 1361 would significantly strengthen the regulatory framework surrounding pharmaceuticals in Georgia, particularly for compounded drugs. The bill mandates that only pharmaceutical grade active ingredients can be used in compounding, which aligns Georgia's regulations with federal standards. It also introduces mechanisms for increased compliance, such as documentation requirements and penalties for violations, including fines and potential revocation of licenses. Consequently, this may improve drug safety for patients by ensuring that compounded medications are prepared under stringent conditions, thus reducing the risk of contamination or misuse.
Summary
House Bill 1361 focuses on regulating the compounding of certain active pharmaceutical ingredients within Georgia. The bill outlines the necessary requirements for manufacturers and wholesalers involved in the sale, transfer, or distribution of compounded drugs. It emphasizes the importance of ensuring that active pharmaceutical ingredients comply with established standards and provides definitions for critical terms such as 'active pharmaceutical ingredient,' 'human drug establishment,' and 'pharmaceutical grade product.' These definitions help clarify the conditions under which compounding can occur and the requisite quality controls that must be met.
Contention
However, the bill may face contention as stakeholders in the pharmacy sector discuss its implications. Concerns might arise regarding the feasibility of compliance for smaller pharmacies, particularly those that may not have the resources to meet the rigorous documentation and testing requirements mandated by HB 1361. Moreover, some may argue that while stricter regulations are essential for safety, they could unintentionally limit access to certain compounded medications that patients rely upon. Balancing patient safety, access to medications, and manageable compliance burdens will be crucial as discussions around this bill continue.
Pharmaceutical products; requiring manufacturers to publish certain list of ingredients; providing administrative, civil, and criminal penalties and remedies. Effective date.
An Act to amend and reenact ยงยง 4.1-1600, 4.1-1602, and 4.1-1603 of the Code of Virginia, relating to medical cannabis program; product labels; delivery.